Migraine medications

Last updated: November 01, 2022

Migraine medications

Internal Medicine

Internal Medicine

Blood transfusion reactions and transplant rejection: Pathology review
Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Non-biologic disease modifying anti-rheumatic drugs (DMARDs)
Osteoporosis medications

Transcript

Watch video only

Migraine medications include a wide variety of drugs used to treat a specific type of headache called migraine.

Migraines are the second most common primary headache.

They’re often preceded by symptoms like irritability, depression, and fatigue that can begin hours to days before the headache itself. Sometimes there can be an aura where people experience strange smells, lights, visual disturbances, or even hallucinations before the onset of the migraine.

The migraine itself usually feels like a pounding or pulsating, typically localized to one side of the head and can last from hours to days.

As if this was not bad enough, these headaches tend to come with nausea and vomiting, irritability, and pain or discomfort with lights, sounds, and smells called photophobia, phonophobia, and osmophobia, respectively.

During childhood, individuals can have nausea and vomiting without the headaches; and that’s called an abdominal migraine.

After a migraine is over, it can leave people feeling sore at the location of the pain and generally fatigued.

To remember the main features of migraines, you can use the mnemonic POUND, where P stands for pulsatile headache, O stands for one-day duration, U stands for unilateral, N for nausea, and D for disabling.

Although the underlying mechanism causing migraines isn’t well understood, there are some clues.

Concentrations of the neurotransmitter, serotonin, increase during the aura, triggering vasoconstriction, and then decrease to lower-than-normal levels during the migraine attack, triggering vasodilation. This change in the blood vessel size may be a trigger for pain receptors, causing the headache.

The initial vasoconstriction may also trigger cortical spreading depression, which is a phenomenon when the brain becomes hypersensitive to certain stimuli like lights, sounds, and smells.

Migraines are often associated with specific triggers like the smell of cigarette smoke, foods like chocolate or cheese, and drinking wine.

Even sleeping too much or too little can sometimes trigger a migraine.

There are two treatment approaches for migraine: acute treatment to help manage the pain; and preventive treatment to keep headaches from happening in the first place, in individuals that have severe, debilitating headaches.

The acute treatment includes common analgesic drugs, triptans, and ergot alkaloids.

For people with mild or moderate symptoms, initial treatment may involve only analgesics, such as NSAIDs or the opioid agonist butorphanol.

Acutely, pain medications work best if they’re used at the first sign of an attack, during the early symptoms, and aura.

If the pain is very severe, triptans or ergotamine, which are serotonin agonists, can be useful because they mimic serotonin to cause vasoconstriction.

So, triptans should be prescribed when people with mild symptoms don’t respond to analgesics, or when symptoms are moderate to severe.

The common suffix for these medications is -triptan, like sumatriptan, zolmitriptan, naratriptan, or rizatriptan.

All of them can be given by mouth, but this may be impractical for people who have nausea or vomiting during the attack. For these situations, subcutaneous injections or a nasal spray of sumatriptan are available.

Triptans are agonists at 5-HT1B and 5HT1D serotonin receptors, therefore preventing vasoactive peptide release, reducing trigeminal nerve activation, and causing vasoconstriction.

Side effects are generally mild, and include mild pain or burning sensations at the site of injection, paresthesia, fatigue, or dizziness, when given per orally.

In addition, not only do they cause vasoconstriction on the blood vessels in the brain, but also in other blood vessels, which can raise blood pressure.

Also, as it causes coronary vasospasm, it can bring about a type of chest pain called angina. Although it’s an uncommon side effect, that’s why triptans are contraindicated in people with hypertension, coronary artery disease, prinzmetal angina, and peripheral vascular disease.

It can also rarely cause myocardial ischemia or infarction, and arrhythmias as well.

Now, when used together with other serotonin receptor agonists, triptans can induce a serotonin syndrome, that comprises of cognitive symptoms, like headache, hallucinations, or coma; somatic symptoms, like tremors or hyperreflexia; and autonomic symptoms like tachycardia, nausea, diarrhoea, shivering, and sweating. So, people who have recently been given ergot alkaloids or other serotonin agonists mustn’t use triptans, at least for 24 hours.

Okay so, sometimes, NSAIDs or triptans aren’t effective to relieve the symptoms. So we can move on to the ergot alkaloids, or simply ‘ergots’, which include ergotamine and dihydroergotamine.

Ergotamine can be administered in sublingual tablets, and dihydroergotamine can be injected or used as a nasal spray.

Ergots are also agonist at 5-HT serotonin receptors. However, they're not specific for 5-HT1 receptors, and that means they have more side effects than triptans.

For example, when they stimulate 5HT3 receptors in the vomiting center of the brain, they can trigger nausea or vomiting.

Also, just like triptans, ergot alkaloids causes vasoconstriction and are contraindicated in people with coronary artery disease or hypertension.

In a similar aspect, as ergot stimulate contraction of the smooth muscle in the wall of blood vessels, they also stimulate contraction of the uterine smooth muscle, an oxytocic effect that can lead to premature labor in pregnant women, causing fetal distress and miscarriage. So, they’re contraindicated during pregnancy.

Ergot alkaloids are widely metabolized in the liver, that’s why they’re contraindicated in patients with liver impairment.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Treatment of acute migraine headache" Am Fam Physician (2011)
  5. "Migraine Headache Prophylaxis" Am Fam Physician (2019)
  6. "Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date" Clin Pharmacol Drug Dev (2017)
  7. "Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences" Expert Review of Neurotherapeutics (2013)
  8. "The pathophysiology of migraine: implications for clinical management" Lancet Neurol (2018)